Metastatic melanoma response to combination therapy with ipilimumab and vemurafenib
Combination therapies for the treatment of metastatic melanoma are a matter of debate nowadays. We report on a stage IV metastatic melanoma patient with the BRAF V600 mutation and a large tumor burden initially treated with two cycles of ipilimumab. Due to dramatic disease progression, demonstrated...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
September-December 2017
|
| In: |
Hellenic journal of nuclear medicine
Year: 2017, Volume: 20, Issue: 3, Pages: 251-253 |
| DOI: | 10.1967/s002449910611 |
| Online Access: | Verlag, kostenfrei, Volltext: https://www.nuclmed.gr/wp-content/uploads/2017/12/13.pdf Resolving-System, kostenfrei, Volltext: http://dx.doi.org/10.1967/s002449910611 
|
| Author Notes: | Christos Sachpekidis MD, Jessica C. Hassel MD, Antonia Dimitrakopoulou-Strauss MD |
| Summary: | Combination therapies for the treatment of metastatic melanoma are a matter of debate nowadays. We report on a stage IV metastatic melanoma patient with the BRAF V600 mutation and a large tumor burden initially treated with two cycles of ipilimumab. Due to dramatic disease progression, demonstrated on interim 18F-FDG PET/CT, vemurafenib was added in the patients therapeutical scheme. After completion of the concurrent ipilimumab and vemurafenib administration, a third 18F-FDG PET/CT showed an impressive metabolic remission of the metastatic disease, reflecting the potential role of the modality in treatment response evaluation of melanoma patients receiving combination therapies. |
|---|---|
| Item Description: | DOI lässt sich nicht aufrufen/05.06.2018 Gesehen am 05.06.2018 |
| Physical Description: | Online Resource |
| DOI: | 10.1967/s002449910611 |